Key Highlights

  • Revenue of USD 21.55 million beat the USD 19.11 million estimate, and loss per share was USD 0.34.
  • Revenue grew 65%, and full-year 2026 Revenue guidance was raised to between USD 78 million and USD 80 million.
  • Gross Margin was 77.3% against 75.9% a year earlier, and adjusted EBITDA was negative USD 7.3 million.
  • Cash, restricted cash and investments totaled USD 80.3 million, with quarterly cash burn of about USD 9 million.

Carlsmed (NASDAQ:CARL), a medical technology company that makes personalized spine surgery implants, reported third quarter 2026 revenue of USD 21.55 million, above the USD 19.11 million estimate. Loss per share was USD 0.34 against an estimated loss of USD 0.39. Revenue grew 65% from USD 13.1 million in the prior-year quarter, and the company raised its full-year 2026 revenue guidance to a range of USD 78 million to USD 80 million.

Nine-month revenue was USD 56.6 million against USD 35.3 million a year earlier, an increase of 60%. Management said gross margin of 77.3% compared with 75.9% in the third quarter of 2025, an expansion of roughly 140 basis points, and described the quarter as the first in which sales growth and margins produced positive operating leverage. The lumbar fusion Franchise represented 88% of third quarter revenue.

Losses, Cash and Borrowing Capacity

Adjusted EBITDA was negative USD 7.3 million against negative USD 8.2 million a year earlier. Management said the measure excludes expenses related to an executive transition and certain legal matters. Research and Development expense was USD 6.4 million against USD 4.4 million in the prior-year quarter, and for the nine months general and administrative expense was USD 23.8 million against USD 11.7 million.

Cash, restricted cash and investments totaled USD 80.3 million at September 30, and management cited cash burn of USD 9 million in the quarter. The filing lists USD 15.6 million of principal outstanding under the Credit Facility and USD 34.4 million available for additional borrowing between the term Loan and the non-formula revolving line, following achievement of a revenue milestone. The accumulated Deficit was USD 132.3 million.

Product Launches and Clinical Data

The company commercially launched its aprevo Lumbar Bi-lateral Posterior System in October and is preparing the full launch of its corra Cervical Plating System. Management described both as meaningful contributors to 2027. Management also credited growth to new surgeons, deeper use among existing customers and the fourth quarter 2025 launch of aprevo cervical.

Management said it delivers aprevo surgical kits to hospitals in about a week after a surgeon approves the surgical plan. It cited a two-year reoperation rate of approximately 6% for patients treated with aprevo, based on unadjusted cross-study comparisons with published literature. The filing states revenue is recognized by the timing of surgical procedures performed with the devices, and the company received USD 49.8 million from customers in the nine months.

Guidance and Items to Follow

Full-year 2026 revenue guidance of USD 78 million to USD 80 million reflects the nine-month results and management's fourth quarter plans. The call referred to certain legal matters in describing its adjusted EBITDA measure, and the 10-Q includes a Legal Proceedings item. Those references are reported here as stated and are flagged for legal review. The items to follow are fourth quarter revenue against the guided range, gross margin, cash burn, borrowing availability, the cervical launch and the executive transition.